Protein kinases are important regulators of cellular proliferation and several, such as HER-2/neu, and the epidermal growth factor receptor (EGFR), have been implicated in the pathogenesis and progression of human breast cancer. We have speculated that other kinases expressed in breast cancer cells may have important functions in the genesis or maintenance of the malignant state. For this reason, we have completed a search for novel kinases in breast cancer tissue and have identified several potentially important species: Our work with the focal adhesion kinase (FAK) is among the more advanced subprojects. We have found that FAK expression is correlated with the invasive and metastatic phenotype and thus may represent a useful marker in early stage breast cancer. Moreover, specific attenuation of FAK expression by antisense oligonucleotides induces apoptosis in cancer cell lines making FAK a rational target for gene directed therapeutics. rak is a src related tyrosine kinase with a nuclear localization signal within its SH2 domain, rak is a unique nuclear tyrosine kinase that binds to the retinoblastoma gene protein, Rb, through its SH3 domain. This implicates rak in cell cycle control and potentially in transformation. STK1 is the human homolog of the cdc2 activating kinase (CAK) which is essential for cdc2/cyclin function. Our investigations show that inhibition of CAK expression results in attenuation of growth in a breast cancer cell line. TK5 is a new JAK kinase, JAK3, expressed in primary breast cancer cells and cell lines, and which is also the important kinase partner for the IL-2/IL-4 receptor. Our discovery of different splice forms with one leading to an enzymatically inactive JAK3 kinase suggests complex signalling through potentially novel cytokine receptors. In this proposal we will focus upon FAK, rak and CAK, characterizing the role of these novel species in breast cancer biology especially in growth and differentiation and to using this knowledge in the design of more specific and directed therapies for breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-05
Application #
5209246
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386

Showing the most recent 10 out of 598 publications